An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Olorofim Administered Via the Oral Route to Healthy Male Subjects
Latest Information Update: 15 Mar 2021
At a glance
- Drugs Olorofim (Primary)
- Indications Coccidioidomycosis; Invasive bronchopulmonary aspergillosis; Mycoses
- Focus Pharmacokinetics
- Acronyms hAME
- Sponsors F2G
Most Recent Events
- 11 Nov 2019 Status changed from recruiting to completed.
- 01 Aug 2019 New trial record